Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Shares Issued (2020 - 2024)

Tango Therapeutics (TNGX) has 5 years of Shares Issued data on record, last reported at $41.7 million in Q1 2024.

  • For Q1 2024, Shares Issued rose 57054.79% year-over-year to $41.7 million; the TTM value through Sep 2024 reached $41.8 million, changed N/A, while the annual FY2023 figure was $689000.0, N/A changed from the prior year.
  • Shares Issued reached $41.7 million in Q1 2024 per TNGX's latest filing, up from $73000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $166.8 million in Q3 2020 and bottomed at $25000.0 in Q2 2020.
  • Average Shares Issued over 5 years is $26.2 million, with a median of $183000.0 recorded in 2021.
  • Peak YoY movement for Shares Issued: crashed 72.45% in 2023, then surged 57054.79% in 2024.
  • A 5-year view of Shares Issued shows it stood at $25000.0 in 2020, then skyrocketed by 304.0% to $101000.0 in 2021, then skyrocketed by 162.38% to $265000.0 in 2022, then crashed by 72.45% to $73000.0 in 2023, then soared by 57054.79% to $41.7 million in 2024.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $41.7 million in Q1 2024, $73000.0 in Q1 2023, and $265000.0 in Q1 2022.